公开(公告)号：DE69713285T2

公开(公告)日：2003-01-02

申请号：DE69713285

申请日：1997-01-09

Applicant: AVENTIS PHARMA INC

Inventor： PRIBISH JAMES R ,  GATES CYNTHIA A ,  WEINTRAUB PHILIPP M

IPC: A61K31/59 ,  A61K31/00 ,  A61P43/00 ,  C07J73/00

Abstract: The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

公开(公告)号：AU6866101A

公开(公告)日：2002-01-08

申请号：AU6866101

申请日：2001-06-21

Applicant: AVENTIS PHARMA INC

Inventor： PEET NORTON P ,  WEINTRAUB PHILIP M ,  BURKHART JOSEPH P ,  GATES CYNTHIA A

IPC: A61P5/28 ,  C07J13/00 ,  A61K31/57

公开(公告)号：PT880540E

公开(公告)日：2002-10-31

申请号：PT97901995

申请日：1997-01-09

Applicant: AVENTIS PHARMA INC

Inventor： GATES CYNTHIA A ,  PRIBISH JAMES R ,  WEINTRAUB PHILIPP M

IPC: A61K31/59 ,  A61K31/00 ,  A61P43/00 ,  C07J73/00

Abstract: The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

公开(公告)号：DK0880540T3

公开(公告)日：2002-10-07

申请号：DK97901995

申请日：1997-01-09

Applicant: AVENTIS PHARMA INC

Inventor： PRIBISH JAMES R ,  GATES CYNTHIA A ,  WEINTRAUB PHILIPP M

IPC: A61K31/59 ,  A61K31/00 ,  A61P43/00 ,  C07J73/00

Abstract: The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

公开(公告)号：DE69713285D1

公开(公告)日：2002-07-18

申请号：DE69713285

申请日：1997-01-09

Applicant: AVENTIS PHARMA INC

Inventor： PRIBISH JAMES R ,  GATES CYNTHIA A ,  WEINTRAUB PHILIPP M

IPC: A61K31/59 ,  A61K31/00 ,  A61P43/00 ,  C07J73/00

Abstract: The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

公开(公告)号：AT219100T

公开(公告)日：2002-06-15

申请号：AT97901995

申请日：1997-01-09

Applicant: AVENTIS PHARMA INC

Inventor： PRIBISH JAMES R ,  GATES CYNTHIA A ,  WEINTRAUB PHILIPP M

IPC: A61K31/59 ,  A61K31/00 ,  A61P43/00 ,  C07J73/00

Abstract: The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

公开(公告)号：ES2178750T3

公开(公告)日：2003-01-01

申请号：ES97901995

申请日：1997-01-09

Applicant: AVENTIS PHARMA INC

Inventor： PRIBISH JAMES R ,  GATES CYNTHIA A ,  WEINTRAUB PHILIPP M

IPC: A61K31/59 ,  A61K31/00 ,  A61P43/00 ,  C07J73/00

Abstract: The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).